Thomas C Hendrickson

US Patent:

8217035, Jul 10, 2012

Filed:

Jan 22, 2007

Appl. No.:

12/161537

Inventors:

Matthew Burger - Emeryville CA, US
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Aaron Smith - Emeryville CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Allan Wagman - Emeryville CA, US
Simon Ng - Emeryville CA, US
Keith Pfister - Emeryville CA, US
Daniel Poon - Emeryville CA, US
Alicia Louie - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Paul Barsanti - Emeryville CA, US
Edwin Iwanowicz - Emeryville CA, US
Wendy Fantl - Emeryville CA, US
Thomas Hendrickson - Emeryville CA, US
Mark Knapp - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Xiaohua Xin - Emeryville CA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/535
C07D 413/14

US Classification:

5142322, 544122

Abstract:

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

US Patent:

8563549, Oct 22, 2013

Filed:

May 14, 2012

Appl. No.:

13/471111

Inventors:

Matthew Burger - Emeryville CA, US
Zhi-Jie Ni - Freemont CA, US
Sabina Pecchi - Oakland CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Aaron Smith - Freemont CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Allan Wagman - Belmont CA, US
Simon Ng - Walnut Creek CA, US
Keith Pfister - San Ramon CA, US
Daniel J. Poon - Piedmont CA, US
Alicia Louie - Emeryville CA, US
Teresa Pick - Danville CA, US
Paul Barsanti - Pleasant Hill CA, US
Edwin Iwanowicz - Emeryville CA, US
Wendy Fantl - Emeryville CA, US
Thomas Hendrickson - Emeryville CA, US
Mark Knapp - Oakland CA, US
Hanne Meritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Bottmingen, CH
Xiahua Xin - Emeryville CA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/535
C07D 413/14

US Classification:

5142322, 544122

Abstract:

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

US Patent:

20070027150, Feb 1, 2007

Filed:

Apr 14, 2006

Appl. No.:

11/404372

Inventors:

Cornelia Bellamacina - Castro Valley CA, US
Abran Costales - El Cerrito CA, US
Brandon Doughan - Eugene OR, US
Susan Fong - Richmond CA, US
Zhenhai Gao - Hercules CA, US
Thomas Hendrickson - Encinitas CA, US
Barry Levine - Lafayette CA, US
Xiaodong Lin - Walnut Creek CA, US
Timothy Machajewski - Martinez CA, US
Christopher McBride - Oakland CA, US
Maureen McKenna - Pinole CA, US
Kris Mendenhall - Concord CA, US
Alice Rico - Castro Valley CA, US
Cynthia Shafer - Moraga CA, US
Yi Xia - Foster City CA, US
Yasheen Zhou - Moraga CA, US

International Classification:

A61K 31/5377
A61K 31/517
C07D 413/02
C07D 403/02

US Classification:

514234200, 544123000, 544284000, 514252170, 514255050, 514266200, 514266220

Abstract:

2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.